Abstract 1864P
Background
Chemotherapy-induced peripheral neuropathy (CIPN) is a commonly problem entity following cancer therapy, among which sensory abnormalities and pain are common and the most suffering issues. Current treatments for CIPN are ineffective. Topical capsaicin is effective for treatment of neuropathic pain in in various type of neuropathy. There are no studies of topical capsaicin cream in CIPN patients. This study assessed the efficacy of topical capsaicin in CIPN patients.
Methods
This study is prospective cohort study. Our study consisted of 50 patients with clinically confirm chemotherapy-induce peripheral neuropathy from various antineoplastic agents. They were treated with topical capsaicin at area of neuropathy and neuropathic pain such as hand, foot or extremities. Baseline characteristics including primary cancer site, neurotoxic agent and cumulative dose, prior treatments were recorded. Symptoms were monitored and followed using the numerical pain rating scale (NPRS), Grading of neurotoxicity by NCI CTCAE version 4.0 and questionnaires of neurotoxicity and quality of life in these toxicities (FACT/GOG-NTX and EORTC-QLQ CIPN20). These documents were collected at baseline, 7 days and 30 days after topical capsaicin application, including toxicities of this agent. A mixed effect linear regression model was applied to identify efficacy of topical capsaicin.
Results
These 50 patients with CIPN reported significant reduction all of scoring at 7 days and 30 days after application. (As table shown) The efficacy and quality of life were constant after 7 days to 30 days after application. 41% of patients has reported toxicities with mostly are burning but those are mild symptoms. Table: 1864P
| 7 days (point) | 95% CI | P-value | 30 days (point) | 95% CI | P-value | |
| NRS | -0.33 | (-0.48) – (-0.18) | <0.01 | -0.35 | (-0.5) – (-0.20) | <0.01 |
| NCI CTCAE | -0.39 | (-0.10) – (0.20) | <0.01 | -0.86 | (-0.15) – (-0.20) | <0.01 |
| FACT/GOG-NTX | -2.06 | (-2.76) – (-1.37) | <0.01 | -2.8 | (-3.50) – (-2.10) | <0.01 |
| EORTC QLQ-CIPN20 | -4.04 | (-5.08) – (-3.01) | <0.01 | -5.12 | (-6.16) – (-4.08) | <0.01 |
Conclusions
Topical capsaicin has efficacy in significant reduction CIPN symptoms and improves quality of life of these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Faculty of medicine, Srinakharinwirot University.
Disclosure
All authors have declared no conflicts of interest.